The global pharmaceutical industry experienced a 5% drop in company filings sentiment in Q2 2024 compared with the previous quarter, according to GlobalData’s analysis of over 1,333 pharmaceutical company filings. GlobalData’s Pharma: Filings Trends & Signals Q2 2024 report delves into earnings call transcripts and quarterly reports within the pharmaceuticals industry, extracting trends, signals, and comparative data to help businesses assess their performance, identify competitive intelligence, evaluate risks, and gain a comprehensive understanding of key industry events. Buy the report here.
Smarter leaders trust GlobalData
Notably, in Q2 2024 the average sentiment dropped from 0.41 to 0.39, indicating a more negative outlook for the industry. This followed flat quarter-on-quarter growth in Q1 2024.
GlobalData’s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative or neutral. Starting at 100 in 2020, an index over 100 is more positive.
Top companies by company filings sentiment in the global pharmaceutical industry, Q2 2024 (Sentiment score)
For further understanding of GlobalData's Pharma: Filings Trends & Signals Q2 2024, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Company Filings Analytics uses machine learning to uncover key insights and track sentiment across millions of regulatory filings and other corporate disclosures for thousands of companies across the world’s largest industries.
